CUSABIO Therapeutic Antibody Discovery Service

Antibody drugs have fewer and fewer adverse reactions because of their high specificity. Therefore, therapeutic antibody has become the predominant class of new drugs developed in recent years. Basically, the whole research and development process of antibody drugs will take 10 years, from the initial identification of targets, to screening of therapeutic antibody candidates for pre-clinical studies, to enter clinical phase Ⅰ/ Ⅱ / Ⅲ trials, and then to complete the final declaration of NDA (new drug application). Throughout the whole process of antibody drug development, therapeutic antibody discovery service is the very beginning of antibody-based drug discovery, and it is crucial as well.

CUSABIO has been working on the development and production of proteins and antibodies for more than 18 years and successfully screened 200+ therapeutic antibody candidates for pharmaceutical companies already, many of which have entered the CMC or IND phases. For some challenging targets, including CLDN18.2, CLDN6, CCR8, SSTR2, DLL3, LY6G6D, ROR1, SEMA4D, GPC3, CD16A and so on, we not only successfully had produced antigens, but also successfully screened corresponding recombinant antibodies already. CUSABIO has 3 platforms for production of transmembrane proteins. Mostly, we have completed 30+ projects of screening services targeting multi-pass transmembrane proteins. So we can confidently promise that CUSABIO has rich experiences in therapeutic antibody discovery service targeting multi-pass transmembrane protein, and we can offer the therapeutic antibody discovery service to you as risk-free, we can promise that we will not charge any fee if we failed in screening.